Message From the Editor-in-Chief
Message From the Editor-in-Chief
2020 Volume 84 Issue 10 Pages 1677-1678
Details
2020 Volume 84 Issue 10 Pages 1677-1678
Dear Colleagues,
On behalf of the Circulation Journal , I would like to report the official 2019 impact factor and the Circulation Journal papers (2017–2018) most frequently quoted in 2019, that substantially contributed to the 2019 impact factor of the Journal.
I would like to report that Circulation Journal has earned an official 2019 Impact Factor (IF) of 2.540 (2019 IF: 3.025). The official ranking places Circulation Journal the 64th among the 138 journals in the Cardiac & Cardiovascular Systems category in 2019 JCR Science Edition (55th among the 136 journals in 2018). I would like to ask readers to use Circulation Journal papers as reference papers in your future submission of manuscripts to any journals.
The following papers, published in 2017–2018, were among the top 28 most frequently quoted papers in 2019, thereby substantially contributing to the 2019 Impact Factor of the Journal (number in the parenthesis denoted the number of quotation in 2017–2018).
1. (25) Yamashita Y, Uozumi R, Hamatani Y, Esato M, Chun YH, Tsuji H, et al. Current status and outcomes of direct oral anticoagulant use in real-world atrial fibrillation patients: Fushimi AF registry. Circ J 2017; 81: 1278–1285.
2. (22) Kaku K, Lee J, Mattheus M, Kaspers S, George J, Woerle HJ; on behalf of the EMPA-REG OUTCOME® Investigators. Empagliflozin and cardiovascular outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: Results from EMPA-REG OUTCOME®. Circ J 2017; 81: 227–234.
3. (20) Hamburg NM, Creager MA. Pathophysiology of intermittent claudication in peripheral artery disease. Circ J 2017; 81: 281–289.
4. (16) Yamashita Y, Morimoto T, Amano H, Takase T, Hiramori S, Kim K, et al; on behalf of COMMAND VTE Registry Investigators. Anticoagulation therapy for venous thromboembolism in the real world: From the COMMAND VTE registry. Circ J 2018; 82: 1262–1270.
5. (15) Heeger CH, Wissner E, Knöll M, Knoop B, Reissmann B, Mathew S, et al. Three-year clinical outcome after 2nd-generation cryoballoon-based pulmonary vein isolation for the treatment of paroxysmal and persistent atrial fibrillation: A 2-center experience. Circ J 2017; 81: 974–980.
6. (14) Lau WB, Ohashi K, Wang Y, Ogawa H, Murohara T, Ma XL, et al. Role of adipokines in cardiovascular disease. Circ J 2017; 81: 920–928.
(14) Nagai T, Yoshikawa T, Saito Y, Takeishi Y, Yamamoto K, Ogawa H, et al; on behalf of the JASPER Investigators. Clinical characteristics, management, and outcomes of Japanese patients hospitalized for heart failure with preserved ejection fraction: A report from the Japanese heart failure syndrome with preserved ejection fraction (JASPER) registry. Circ J 2018; 82: 1534–1545.
8. (12) Kario K, Tomitani N, Kanegae H, Ishii H, Uchiyama K, Yamagiwa K, et al. Comparative effects of an angiotensin II receptor blocker (ARB)/diuretic vs. ARB/calcium-channel blocker combination on uncontrolled nocturnal hypertension evaluated by information and communication technology-based nocturnal home blood pressure monitoring: The NOCTURNE study. Circ J 2017; 81: 948–957.
(12) Okumura Y, Yokoyama K, Matsumoto N, Tachibana E, Kuronuma K, Oiwa K, et al; for the SAKURA AF Registry Investigators. Three-year clinical outcomes associated with warfarin vs. direct oral anticoagulant use among Japanese patients with atrial fibrillation: Findings from the SAKURA AF registry. Circ J 2018; 82: 2500–2509.
10. (11) Fukushima N, Ono M, Saiki Y, Sawa Y, Nunoda S, Isobe M. Registry report on heart transplantation in Japan (June 2016). Circ J 2017; 81: 298–303.
(11) Ichibori Y, Mizote I, Maeda K, Onishi T, Ohtani T, Yamaguchi O, et al. Clinical outcomes and bioprosthetic valve function after transcatheter aortic valve implantation under dual antiplatelet therapy vs. aspirin alone. Circ J 2017; 81: 397–404.
12. (10) De Rosa R, Vasa-Nicotera M, Leistner DM, Reis SM, Thome CE, Boeckel JN, et al. Coronary atherosclerotic plaque characteristics and cardiovascular risk factors: Insights from an optical coherence tomography study. Circ J 2017; 81: 1165–1173.
(10) Inomata T, Ikeda Y, Kida K, Shibagaki Y, Sato N, Kumagai Y, et al; for the Kanagawa Aquaresis Investigators. Effects of additive tolvaptan vs. increased furosemide on heart failure with diuretic resistance and renal impairment: Results from the K-STAR study. Circ J 2018; 82: 159–167.
(10) Lee CH, Cheng CL, Kao Yang YH, Chao TH, Chen JY, Li YH. Cardiovascular and bleeding risks in acute myocardial infarction newly treated with ticagrelor vs. clopidogrel in Taiwan. Circ J 2018; 82: 747–756.
(10) Pignon B, Sevestre MA, Kanagaratnam L, Pernod G, Stephan D, Emmerich J, et al. Autologous bone marrow mononuclear cell implantation and its impact on the outcome of patients with critical limb ischemia: Results of a randomized, double-blind, placebo-controlled trial. Circ J 2017; 81: 1713–1720.
16. (9) Chen C, Wei J, AlBadri A, Zarrini P, Bairey Merz CN. Coronary microvascular dysfunction: Epidemiology, pathogenesis, prognosis, diagnosis, risk factors and therapy. Circ J 2017; 81: 3–11.
(9) Darocha S, Pietura R, Pietrasik A, Norwa J, Dobosiewicz A, Piłka M, et al. Improvement in quality of life and hemodynamics in chronic thromboembolic pulmonary hypertension treated with balloon pulmonary angioplasty. Circ J 2017; 81: 552–557.
(9) Ferrari R, Balla C, Malagù M, Guardigli G, Morciano G, Bertini M, et al. Reperfusion damage: A story of success, failure, and hope. Circ J 2017; 81: 131–141.
(9) Curcio A, Santarpia G, Indolfi C. The Brugada syndrome: From gene to therapy. Circ J 2017; 81: 290–297.
(9) Minamisawa M, Miura T, Motoki H, Ueki Y, Nishimura H, Shimizu K, et al. Geriatric nutritional risk index predicts cardiovascular events in patients at risk for heart failure. Circ J 2018; 82: 1614–1622.
(9) Furuhashi M, Yuda S, Muranaka A, Kawamukai M, Matsumoto M, Tanaka M, et al. Circulating fatty acid-binding protein 4 concentration predicts the progression of carotid atherosclerosis in a general population without medication. Circ J 2018; 82: 1121–1129.
(9) Yasuoka H, Shirai Y, Tamura Y, Takeuchi T, Kuwana M. Predictors of favorable responses to immunosuppressive treatment in pulmonary arterial hypertension associated with connective tissue disease. Circ J 2018; 82: 546–554.
23. (8) Kokubo Y, Watanabe M, Higashiyama A, Nakao YM, Kusano K, Miyamoto Y. Development of a basic risk score for incident atrial fibrillation in a Japanese general population: The Suita study. Circ J 2017; 81: 1580–1588.
(8) Fujisue K, Sugamura K, Kurokawa H, Matsubara J, Ishii M, Izumiya Y, et al. Colchicine improves survival, left ventricular remodeling, and chronic cardiac function after acute myocardial infarction. Circ J 2017; 81: 1174–1182.
(8) Yazaki K, Otsuka M, Kataoka S, Kahata M, Kumagai A, Inoue K, et al. Applicability of 3-dimensional quantitative coronary angiography-derived computed fractional flow reserve for intermediate coronary stenosis. Circ J 2017; 81: 988–992.
(8) Yoshimura S, Koga M, Sato S, Todo K, Yamagami H, Kumamoto M, et al; for the SAMURAI Study Investigators. Two-year outcomes of anticoagulation for acute ischemic stroke with nonvalvular atrial fibrillation: SAMURAI-NVAF study. Circ J 2018; 82: 1935–1942.
(8) Lin YN, Chen YH, Wang HJ, Hung JS, Chang KC, Lo PH. Atrial septostomy for left atrial decompression during extracorporeal membrane oxygenation by Inoue balloon catheter. Circ J 2017; 81: 1419–1423.
(8) Hatazawa K, Tanaka H, Nonaka A, Takada H, Soga F, Hatani Y, et al. Baseline global longitudinal strain as a predictor of left ventricular dysfunction and hospitalization for heart failure of patients with malignant lymphoma after anthracycline therapy. Circ J 2018; 82: 2566–2574.
The Editorial Team looks forward to receiving manuscripts with high scientific impact from all over the world.
